MX2024010180A - Sal y forma cristalina del compuesto inhibidor de dipeptidil peptidasa. - Google Patents

Sal y forma cristalina del compuesto inhibidor de dipeptidil peptidasa.

Info

Publication number
MX2024010180A
MX2024010180A MX2024010180A MX2024010180A MX2024010180A MX 2024010180 A MX2024010180 A MX 2024010180A MX 2024010180 A MX2024010180 A MX 2024010180A MX 2024010180 A MX2024010180 A MX 2024010180A MX 2024010180 A MX2024010180 A MX 2024010180A
Authority
MX
Mexico
Prior art keywords
salt
crystal form
inhibitor compound
dipeptidyl peptidase
peptidase inhibitor
Prior art date
Application number
MX2024010180A
Other languages
English (en)
Spanish (es)
Inventor
Jiang Fan
Zheng Gong
Fengfei Zhu
Ying Dou
Original Assignee
Haisco Pharmaceuticals Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Haisco Pharmaceuticals Pte Ltd filed Critical Haisco Pharmaceuticals Pte Ltd
Publication of MX2024010180A publication Critical patent/MX2024010180A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/10—Seven-membered rings having the hetero atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cooling Or The Like Of Semiconductors Or Solid State Devices (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2024010180A 2022-02-22 2023-02-21 Sal y forma cristalina del compuesto inhibidor de dipeptidil peptidasa. MX2024010180A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202210160862 2022-02-22
PCT/CN2023/077409 WO2023160542A1 (zh) 2022-02-22 2023-02-21 二肽基肽酶抑制剂化合物的盐及晶型

Publications (1)

Publication Number Publication Date
MX2024010180A true MX2024010180A (es) 2024-08-27

Family

ID=87764787

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024010180A MX2024010180A (es) 2022-02-22 2023-02-21 Sal y forma cristalina del compuesto inhibidor de dipeptidil peptidasa.

Country Status (13)

Country Link
US (1) US20250188067A1 (cg-RX-API-DMAC7.html)
EP (1) EP4484414A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025508792A (cg-RX-API-DMAC7.html)
KR (1) KR20240153351A (cg-RX-API-DMAC7.html)
CN (1) CN118660873A (cg-RX-API-DMAC7.html)
AU (1) AU2023225835A1 (cg-RX-API-DMAC7.html)
CA (1) CA3243683A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024002490A1 (cg-RX-API-DMAC7.html)
IL (1) IL314852A (cg-RX-API-DMAC7.html)
MX (1) MX2024010180A (cg-RX-API-DMAC7.html)
TW (1) TW202342466A (cg-RX-API-DMAC7.html)
WO (1) WO2023160542A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202407225B (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025506307A (ja) * 2022-02-22 2025-03-07 ハイスコ ファーマスーティカル プライベート リミテッド 含窒素複素環化合物の調製方法
JP2026503035A (ja) 2023-01-06 2026-01-27 インスメッド インコーポレイテッド 新規な可逆性dpp1阻害剤及びその用途
WO2025162472A1 (en) 2024-01-31 2025-08-07 Insmed Incorporated Linear dipeptidyl peptidase 1 inhibitors and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7902181B2 (en) * 2007-12-12 2011-03-08 Astrazeneca Ab Compounds 010
NO2699580T3 (cg-RX-API-DMAC7.html) * 2014-01-24 2018-02-24
PL4129989T3 (pl) * 2020-08-26 2025-02-24 Haisco Pharmaceuticals Pte. Ltd. Pochodna nitrilu działająca jako inhibitor dipeptydylopeptydazy 1 i jej zastosowanie
CN114106005B (zh) * 2020-08-26 2025-08-01 西藏海思科制药有限公司 一种作为二肽基肽酶1抑制剂的腈衍生物及其用途
CN114591315A (zh) * 2020-12-04 2022-06-07 瑞石生物医药有限公司 一种组织蛋白酶c小分子抑制剂
WO2022166721A1 (zh) * 2021-02-05 2022-08-11 南京明德新药研发有限公司 含1,4-氧杂氮杂环庚烷的并环类衍生物

Also Published As

Publication number Publication date
EP4484414A1 (en) 2025-01-01
TW202342466A (zh) 2023-11-01
IL314852A (en) 2024-10-01
AU2023225835A1 (en) 2024-10-03
CL2024002490A1 (es) 2024-12-13
ZA202407225B (en) 2025-12-17
KR20240153351A (ko) 2024-10-22
CA3243683A1 (en) 2025-01-22
JP2025508792A (ja) 2025-04-10
US20250188067A1 (en) 2025-06-12
WO2023160542A1 (zh) 2023-08-31
EP4484414A4 (en) 2026-01-28
CN118660873A (zh) 2024-09-17

Similar Documents

Publication Publication Date Title
CL2024002490A1 (es) Sal y forma cristalina del compuesto inhibidor de dipeptidil peptidasa
SA522432955B1 (ar) Kras g12c مثبطات
JOP20240210A1 (ar) مثبطات kras
MX2025001619A (es) Inhibidor de pde4b y uso del mismo
MX2024004846A (es) Compuesto tetraciclico que contiene nitrogeno, metodo de preparacion del mismo y uso medico del mismo.
JOP20200154B1 (ar) مركبات ومشتقات بيريدو بيريمينون بها استبدال ببنزيل أمينو جديدة كمثبطات sos1
EP4643882A3 (en) Capsid inhibitors for the prevention of hiv
CO2026005655A2 (es) Inhibidor de pan-kras y uso del mismo en medicinas
CO2022012975A2 (es) Derivados de biarilo como inhibidores de la interacción proteína-proteína de yap/taz-tead
MX2020012966A (es) Combinacion, composicion y preparacion de combinacion farmaceutica que comprende activador de glucocinasa e inhibidor de sglt-2, metodos de preparacion y usos de las mismas.
MX2023007853A (es) Compuesto heterociclico puenteado que contiene nitrogeno, metodo de preparacion y uso medico del mismo.
MX2024014861A (es) Inhibidor de la prmt5 de tres anillos fusionados que contiene nitrogeno, y metodo de preparacion del mismo y uso farmaceutico del mismo
MX2019008853A (es) Metodos para la administracion de ciertos inhibidores de proteina transportadora transportador de monoamina vesicular-2 (vmat2).
MX2024001777A (es) Derivado de sulfonamida, metodo de preparacion y uso medico del mismo.
CO6220933A2 (es) Formulaciones de dosis unitaria y metdods para el tratamiento de la trombosis con un inhibidor oral del facror xa
CO2021009083A2 (es) Compuestos y su uso para el tratamiento de la deficiencia de α1-antitripsina
MX2020009530A (es) Inhibidores de la o-glicoproteína-2-acetamido-2-desoxi-3-dglicopir anosidasa.
GEP20207095B (en) Fused bicyclic heteroaryl derivatives having activity as phd inhibitors
AR131639A1 (es) Inhibidores de kif18a y usos de los mismos
MX2024006975A (es) Inhibidor de cdk9 y uso del mismo.
MX2021006724A (es) Compuestos de halo-alilamina y uso de los mismos.
RU2017117559A (ru) Бензопроизводные с шестичленным кольцом в качестве ингибитора dpp-4 и их применение
ECSP066330A (es) Derivados de 1-sulfonilindol, su preparación y su uso como lingados de 5-ht-6
MX2023011920A (es) Compuestos de 1,3,4-oxadiazol tiocarbonilo como inhibidores de histona deacetilasa 6, y composicion farmaceutica que los comprende.
CL2024001073A1 (es) Inhibidores de la replicación del virus de inmunodeficiencia humana